Divi’s Laboratories Share Price Target 2026: Analyst Consensus, Bull Case & Bear Case

Updated: 13 Apr 2026 • 12:37 pm

Posted by:

Divi’s Laboratories Share Price Target 2026: Analyst Consensus, Bull Case & Bear Case

Divi’s Laboratories (Pharma / CDMO) is trading at Rs 4,200 as of April 2026, with a 52-week range from Rs 3,900 to Rs 6,200 and a 1-year return of -32%. The analyst consensus 12-month Divi’s Laboratories share price target stands at Rs 5,000-5,800 — implying meaningful potential movement from current levels.

Whether you are a long-term holder reassessing your position or a new investor evaluating entry levels, understanding where analysts see Divi’s Laboratories heading over the next 12-24 months requires looking beyond the CMP. This article covers the key catalysts and risks, technical levels, institutional positioning, and a structured breakdown of the short-term, 12-month, and long-term Divi’s Laboratories share price targets.

Click Here — Get Free Investment Predictions on Univest.

Table of Contents

Divi’s Laboratories Key Data — CMP, Valuation, Fundamentals

Parameter	Value
CMP (April 2026)	Rs 4,200
52-Week High	Rs 6,200
52-Week Low	Rs 3,900
1-Year Return	-32%
Trailing P/E	52x
Price-to-Book	7.8x
Market Cap	Rs 1.1L Cr
Sector	Pharma / CDMO
Promoter Holding	51.9%
FII Holding	22.6%
DII Holding	18.4%

Track live Divi’s Laboratories fundamentals and analyst ratings on the Univest Screener.

Divi’s Laboratories Share Price Targets — Short-Term, 12-Month & Long-Term

Access premium analyst research on Univest.

Scenario	Target	Basis
Short-Term (3-6M)	Rs 5,000	Technical support; near-term catalyst
12-Month Consensus	Rs 5,000-5,800	Analyst consensus based on current fundamentals
Bull Case (FY28)	Rs 7,500	Full execution of growth catalysts below
Bear Case	Rs 3,200	Materialisation of key risks below

Bull Case — What Has to Go Right for Divi’s Laboratories

1. CDMO business ramping

first large-scale Phase 3 CDMO batches at Vizag facility creating future NDA-commercial pipeline

2. China+1 strategy benefiting Divi’s

US pharma companies actively qualifying Indian API sources

3. Nutraceuticals API business expanding into US branded nutrition market

Nutraceuticals API business expanding into US branded nutrition market

4. Revenue and PAT recovery expected in FY27 as Chinese API pricing pressure normalises

Revenue and PAT recovery expected in FY27 as Chinese API pricing pressure normalises

5. Promoter family’s technical background in complex synthesis providing genuine IP advantage

Promoter family’s technical background in complex synthesis providing genuine IP advantage

Bear Case — Key Risks to the Divi’s Laboratories Share Price Target

Risk 1: API pricing remaining depressed if Chinese overcapacity persists longer than expected

API pricing remaining depressed if Chinese overcapacity persists longer than expected

Risk 2: CDMO programme delays pushing revenue contribution to FY29-30 instead of FY28

CDMO programme delays pushing revenue contribution to FY29-30 instead of FY28

Institutional Sentiment and Technical Analysis

Divi’s Laboratories has 22.6% FII holding and 18.4% DII holding. High FII ownership of 22.6% means the stock is sensitive to global risk-off events — FII selling can be disproportionate to any specific negative news.

Technically, Divi’s Laboratories is trading at Rs 4,200 against a 52-week range of Rs 3,900 to Rs 6,200. The -32% 1-year return positions the stock in negative territory — creating both risk of further downside and opportunity for mean reversion. The 12-month analyst target of Rs 5,000-5,800 implies the stock is expected to recover meaningfully from current depressed levels.

Download the Univest iOS App or Univest Android App for real-time research and analyst updates.

Conclusion — Our View on ${name} Share Price Target

Divi’s Labs at Rs 4,200 and 52x trailing P/E on suppressed earnings looks expensive. But at 15-18x FY28 earnings (when CDMO ramp is expected to be meaningful), the stock is attractively priced. The China+1 API qualification opportunity and CDMO business represent multi-year growth drivers. 12-month target of Rs 5,000-5,800 requires FY27 earnings recovery evidence.

Subscribe to Univest Pro for SEBI-registered analyst recommendations — entry, target, stop-loss.

Frequently Asked Questions

Q1. What is Divi’s Laboratories share price target 2026?

Divi’s Laboratories share price target for 2026 is Rs 5,000-5,800 based on analyst consensus. The bull case target is Rs 7,500 and the bear case is Rs 3,200. These are analyst estimates, not guaranteed returns.

Q2. Is Divi’s Laboratories a good buy now?

Divi’s Laboratories is trading at Rs 4,200 against a 52-week range of Rs 3,900 to Rs 6,200. Analyst consensus target of Rs 5,000-5,800 implies upside from current levels. Consult a SEBI-registered financial advisor before investing.

Q3. What is Divi’s Laboratories’s current valuation?

Divi’s Laboratories trades at a trailing P/E of 52x and price-to-book of 7.8x with a market capitalisation of Rs 1.1L Cr. The stock’s valuation relative to earnings growth determines the appropriate entry point.

Q4. What are the key risks for Divi’s Laboratories?

Key risks for Divi’s Laboratories include the factors outlined in the Bear Case section of this article. API pricing remaining depressed if Chinese overcapacity persists longer than expected is the primary near-term risk to watch.

Q5. Where can I track Divi’s Laboratories share price live?

Track Divi’s Laboratories share price live, quarterly results, FII/DII activity, and analyst ratings on the Univest Screener at univest.in/screeners. Download the Univest iOS or Android App for daily research.

Disclaimer: Investment in the share market is subject to risk. This article is for informational and educational purposes only and does not constitute investment advice. All analyst targets are estimates and may change. Verify all numbers before investing. Consult a SEBI-registered financial advisor before making any investment decisions.

For more stock research, visit Univest Blogs.